ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2021, 'HCV Elimination in Australia', in Hepatitis C: Epidemiology, Prevention and Elimination Volume 1, Springer, https://doi.org/10.1007/978-3-030-64649-3_11
,2020, 'Global elimination of hepatitis C virus by 2030: The optimistic view', in Clinical Dilemmas in Viral Liver Disease, Second Edition, pp. 238 - 243, http://dx.doi.org/10.1002/9781119533481.ch40
,2020, 'Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: How effective are they?', in Clinical Dilemmas in Viral Liver Disease, Second Edition, pp. 106 - 111, http://dx.doi.org/10.1002/9781119533481.ch18
,2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
,2017, 'Investigational antiviral drugs', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press
,2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press
,2014, 'Exposure and acute viral hepatitis', in HIV, Viral Hepatitis and STIs: A Guide for Primary Care
,2025, 'Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies', Proceedings of the National Academy of Sciences of the United States of America, 122, http://dx.doi.org/10.1073/pnas.2417544121
,2025, 'Decentralised COVID-19 molecular point-of-care testing: lessons from implementing a primary care-based network in remote Australian communities', Medical Journal of Australia, http://dx.doi.org/10.5694/mja2.52589
,2024, 'Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023)', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofae665
,2024, 'Hepatitis C treatment outcome among people in prison: The SToP-C study', Liver International, 44, pp. 2996 - 3007, http://dx.doi.org/10.1111/liv.16074
,2024, 'Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia', The Lancet Regional Health - Western Pacific, 51, http://dx.doi.org/10.1016/j.lanwpc.2024.101185
,2024, 'Reinfection after Hepatitis C Virus Treatment - Keep Testing, Keep Treating', JAMA Network Open, 7, pp. e2430290, http://dx.doi.org/10.1001/jamanetworkopen.2024.30290
,2024, 'Prevalence of hepatitis C virus exposure and infection among Indigenous and tribal populations: a global systematic review and meta-analysis', Public Health, 233, pp. 65 - 73, http://dx.doi.org/10.1016/j.puhe.2024.04.035
,2024, 'Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104468
,2024, 'Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104394
,2024, 'Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study', Drug and Alcohol Review, 43, pp. 1019 - 1028, http://dx.doi.org/10.1111/dar.13828
,2024, 'Corrigendum to “Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales” [JHEP Reports 4 (2022)] (JHEP Reports (2022) 4(10), (S2589555922001240), (10.1016/j.jhepr.2022.100552))', JHEP Reports, 6, http://dx.doi.org/10.1016/j.jhepr.2024.101022
,2024, 'Patient and healthcare provider perceptions of acceptability of fingerstick point-of-care hepatitis C testing at Aboriginal Community Controlled Health Services in Australia', International Journal of Drug Policy, 125, http://dx.doi.org/10.1016/j.drugpo.2024.104335
,2024, 'Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies', The Lancet HIV, 11, pp. e106 - e116, http://dx.doi.org/10.1016/S2352-3018(23)00267-9
,2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895
,2024, 'Paving the way for quality assured, decentralised point-of-care testing for infectious disease in primary care - Real world lessons from remote Australia', Expert Review of Molecular Diagnostics, http://dx.doi.org/10.1080/14737159.2024.2403091
,2023, 'Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients', Nature Communications, 14, http://dx.doi.org/10.1038/s41467-023-36295-5
,2023, 'Clinical variation in the early assessment and management of suspected community-acquired meningitis: a multicentre retrospective study', Internal Medicine Journal, 53, pp. 2298 - 2306, http://dx.doi.org/10.1111/imj.16076
,2023, 'The APPRISE Virtual Biobank for Infectious Diseases', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.66
,2023, 'Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study', Drug and Alcohol Review, 42, pp. 1617 - 1632, http://dx.doi.org/10.1111/dar.13723
,2023, 'Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study', JHEP Reports, 5, http://dx.doi.org/10.1016/j.jhepr.2023.100867
,2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890, http://dx.doi.org/10.1097/QAD.0000000000003651
,2023, 'Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study', Pathogens, 12, pp. 1248, http://dx.doi.org/10.3390/pathogens12101248
,2023, 'Hepatitis C', The Lancet, 402, pp. 1085 - 1096, http://dx.doi.org/10.1016/S0140-6736(23)01320-X
,2023, 'Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study', Journal of the International AIDS Society, 26, pp. e26168, http://dx.doi.org/10.1002/jia2.26168
,2023, 'Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review', Clinical Infectious Diseases, 77, pp. S238 - S244, http://dx.doi.org/10.1093/cid/ciad344
,2023, 'Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19', Microorganisms, 11, pp. 1985, http://dx.doi.org/10.3390/microorganisms11081985
,2023, 'Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis', The Lancet Microbe, 4, pp. e622 - e631, http://dx.doi.org/10.1016/S2666-5247(23)00108-8
,2023, 'Highly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity', ImmunoHorizons, 7, pp. 508 - 527, http://dx.doi.org/10.4049/immunohorizons.2300034
,2023, 'Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study', The Lancet Public Health, 8, pp. e294 - e304, http://dx.doi.org/10.1016/S2468-2667(23)00056-7
,2023, 'Universal hepatitis C virus screening and treatment as part of prenatal care', The Lancet Gastroenterology and Hepatology, 8, pp. 295 - 297, http://dx.doi.org/10.1016/S2468-1253(22)00421-6
,2023, 'The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe (vol 75, pg 2027, 2022)', CLINICAL INFECTIOUS DISEASES, http://dx.doi.org/10.1093/cid/ciac730
,2023, 'High activation levels maintained in receptor-binding domain–specific memory B cells in people with severe coronavirus disease 2019', Immunology and Cell Biology, 101, pp. 142 - 155, http://dx.doi.org/10.1111/imcb.12607
,2023, 'A unique cytotoxic CD4+ T cell-signature defines critical COVID-19', Clinical and Translational Immunology, 12, pp. e1463, http://dx.doi.org/10.1002/cti2.1463
,2023, 'Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)', Journal of Viral Hepatitis, 30, pp. 386 - 396, http://dx.doi.org/10.1111/jvh.13803
,2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72, http://dx.doi.org/10.1111/jvh.13761
,2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246
,2022, 'Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study', International Journal of Drug Policy, 109, http://dx.doi.org/10.1016/j.drugpo.2022.103828
,2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272
,2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales', JHEP Reports, 4, http://dx.doi.org/10.1016/j.jhepr.2022.100552
,2022, 'Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort', Health Science Reports, 5, http://dx.doi.org/10.1002/hsr2.719
,2022, 'Persistent high-level shedding of cultivable SARS-CoV-2 Delta virus 33 days after onset of COVID-19 in a hospitalized patient with pneumonia', Journal of Medical Virology, 94, pp. 4043 - 4046, http://dx.doi.org/10.1002/jmv.27832
,2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543
,2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705
,